Chun-Che Lin

Chun-Che Lin


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2011 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
TCTsung‐Ming Chen
Tsung‐Ming Chen
CLChun-Che Lin
Chun-Che Lin
PHPi‐Teh Huang
Pi‐Teh Huang
CWChen‐Fan Wen
Chen‐Fan Wen

13 April 2011 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
TCTsung‐Ming Chen
Tsung‐Ming Chen
CLChun-Che Lin
Chun-Che Lin
PHPi‐Teh Huang
Pi‐Teh Huang
CWChen‐Fan Wen
Chen‐Fan Wen

22 November 2012 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
TCT.‐M. Chen
T.‐M. Chen
CCC.‐C. Chang
C.‐C. Chang
PHP.‐T. Huang
P.‐T. Huang
CWC.‐F. Wen
C.‐F. Wen
CLChun-Che Lin
Chun-Che Lin
Summary: Background: REACH‐B [Risk Estimation for Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B] scoring system was developed to predict the risk of HCC in noncirrhotic chronic hepatitis B (CHB) patients.Aim: To evaluate the discriminatory performance of REACH‐B scoring system in classifying anti‐viral treatment eligibility of CHB patients according to the 2012 Asian Pacific Association for the Study of the Liver (APASL) treatment guideline.Methods: A total of 904 noncirrhotic CHB were enrolled. Patients' age, gender, liver biochemistry, HBeAg status and HBV DNA levels were recorded.Results: The minimum REACH‐B risk score for patients to be eligible for anti‐viral treatment was 7 for HBeAg‐positive and 6 for HBeAg‐negative patients. Among them, increasing REACH‐B score was not significantly associated with eligibility for treatment [adjusted odds ratio (OR): 1.210, 95% confidence interval (CI): 0.979–1.494, P = 0.078] in HBeAg‐positive patients, as shown by logistic regression analysis after adjusting for gender. In HBeAg‐negative patients, REACH‐B score significantly predicted the treatment eligibility (adjusted OR: 1.783, 95% CI: 1.607–1.979, P < 0.001). Discriminatory ability of REACH‐B score to classify eligibility was poor for HBeAg‐positive patients ≥40 years [area under receiver operating characteristic (AUC): 0.664, 95% CI: 0.533–0.795], but good/excellent for HBeAg‐positive patients <40 years (AUC: 0.903; 95% CI: 0.841–0.964), HBeAg‐negative patients ≥45 years (AUC: 0.883; 95% CI: 0.848–0.917) and HBeAg‐negative patients <45 years (AUC: 0.907; 95% CI: 0.874–0.940).Conclusion: The discriminatory performance of the REACH‐B scoring system in classifying anti‐viral treatment eligibility based on the 2012 APASL guideline was good/excellent, except for ≥40 years old HBeAg‐positive patients.

31 July 2019 in BMC Public Health
Verified
Journal Article
Open access
PDF file
Chi-Chih WangChi-Chih Wang
Chi-Chih Wang
MTMing-Chang Tsai
Ming-Chang Tsai
SWShao-Chuan Wang
Shao-Chuan Wang
CPChengming Peng
Chengming Peng
HLHsiang-Lin Lee
Hsiang-Lin Lee
Wen-Wei SungWen-Wei Sung
Wen-Wei Sung
The mortality-to-incidence ratio (MIR) is a marker that reflects the clinical outcome of cancer treatment. MIR as a prognostic marker is more accessible when compared with long-term follow-up survival surveys. Theoretically, countries with good health care systems would have favorable outcomes for cancer; however, no report has yet demonstrated an association between gallbladder cancer MIR and the World’s Health System ranking. We used linear regression to analyze the correlation of MIRs with the World Health Organization (WHO) rankings and total expenditures on health/gross domestic product (e/GDP) in 57 countries selected according to the data quality. The results showed high crude rates of incidence/mortality but low MIR in more developed regions. Among continents, Europe had the highest crude rates of incidence/mortality, whereas the highest age-standardized rates (ASR) of incidence/mortality were in Asia. The MIR was lowest in North America and highest in Africa (0.40 and 1.00, respectively). Furthermore, favorable MIRs were correlated with good WHO rankings and high e/GDP (p = 0.01 and p = 0.030, respectively). The MIR variation for gallbladder cancer is therefore associated with the ranking of the health system and the expenditure on health.

15 July 2014 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
TCT.‐M. Chen
T.‐M. Chen
CLChun-Che Lin
Chun-Che Lin

15 March 2019 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
Chi-Chih WangChi-Chih Wang
Chi-Chih Wang
MTMing-Chang Tsai
Ming-Chang Tsai
Wen-Wei SungWen-Wei Sung
Wen-Wei Sung
TYTzu-Wei Yang
Tzu-Wei Yang
HCHsuan-Yi Chen
Hsuan-Yi Chen
CLChun-Che Lin
Chun-Che Lin
Risk of cholangiocarcinoma in patients undergoing therapeutic endoscopic retrograde cholangiopancreatography or cholecystectomy: A population based study